Search
SOLACI Congress
HomePharmacologyAntiplatelet

Antiplatelet

View Category

Antiplatelet

Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Vascular Disease

Peripheral vascular disease is considered as a manifestation of systemic atherosclerosis associated with adverse events, both cardiovascular...
solaci -
Learn More
Acute coronary syndromes

Ticagrelor vs. Prasugel: Similar Safety and Efficacy in Primary Angioplasty

No randomized head-to-head study comparing the efficacy and safety of ticagrelor and prasugrel has been carried out...
solaci -
Learn More
Antiplatelet

Is It Safe to Discontinue Ticagrelor One Day Before CABG?

Courtesy of Dr. Agustín Vecchia. Nearly 10% of patients with acute coronary syndrome (ACS) require surgery. Managing periprocedural...
solaci -
Learn More
Antiplatelet

Prasugrel vs. Ticagrelor in Diabetics with Heart Disease

Diabetic patients are increased risk of thrombotic events, which is why an effective antiplatelet therapy is crucial...
solaci -
Learn More
Antiplatelet

Procedural Complexity Affects Decision-Making Regarding DAPT Duration

Much of the speculation around the way of individualizing dual antiplatelet therapy (DAPT) duration after coronary angioplasty...
solaci -
Learn More
Antiplatelet

Dual Antiplatelet Therapy in Men and Women: Are There Differences?

Courtesy of Dr. Agustín Vecchia.   Currently, the duration of dual antiplatelet therapy (DAPT) after stent placement is one of the...
solaci -
Learn More
Antiplatelet

Anticoagulation and PCI: How Long Should Triple Therapy Last?

The aim of this study was to compare clinical outcomes in relation to the duration of triple...
solaci -
Learn More
Acute coronary syndromes

Intracoronary Abciximab reduces events in diabetics during PPCI

Diabetic patients have an increased risk of future cardiovascular events after an ST elevation MI. Administration of...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Dr. Omar Tupayachi - 0
Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy